Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | FBP1 | P09467 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1508272 | 0.88 | NR3C1 (0.33) | NR3C1GAAHTTL3MBTL1MEN1 | |
| SCHEMBL1508152 | 0.80 | CYP19A1 (0.34) | — | |
| SCHEMBL1508144 | 0.74 | GAA (0.35) | NR3C1GAAHTTL3MBTL1MEN1 | |
| SCHEMBL14075368 | 0.73 | MEN1 (0.36) | NR3C1GAAHTTL3MBTL1MEN1 | |
| SCHEMBL1508228 | 0.69 | RBBP9 (0.34) | NR3C1GAAHTTL3MBTL1MEN1 | |
| SCHEMBL12833790 | 0.69 | MEN1 (0.34) | NR3C1GAAHTTL3MBTL1MEN1 | |
| SCHEMBL1508227 | 0.69 | MEN1 (0.34) | GAAHTTL3MBTL1MEN1KMT2A | |
| SCHEMBL1508248 | 0.69 | KEAP1 (0.33) | MEN1KMT2ACYP3A4CYP2D6MAPT | |
| SCHEMBL1508219 | 0.67 | FBP1 (0.36) | GAAHTTL3MBTL1MEN1KMT2A | |
| SCHEMBL2984624 | 0.65 | KCNH2 (0.41) | NR3C1GAAHTTL3MBTL1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1911740-A1 | POTASSIUM CHANNEL MODULATORS | NeuroSearch A/S (DK) | 2008-04-16 | — | — | EP | claimed |
| US-20070161607-A1 | Potassium channel modulators | SANIONA A/S (DK) | 2007-07-12 | — | — | US | claimed |
| US-20050009816-A1 | Potassium channel modulators | SANIONA A/S (DK) | 2005-01-13 | — | — | US | claimed |
| EP-1465863-A1 | POTASSIUM CHANNEL MODULATORS | Poseidon Pharmaceuticals A/S (DK) | 2004-10-13 | — | — | EP | claimed |
| WO-2003059873-A1 | POTASSIUM CHANNEL MODULATORS | POSEIDON PHARMACEUTICALS A/S (DK) | 2003-07-24 | — | — | WO | claimed |
| EP-2292595-A1 | Potassium channel modulators | NeuroSearch AS (DK) | 2011-03-09 | — | — | EP | disclosed |
| EP-2292595-A1 | Potassium channel modulators | NeuroSearch AS (DK) | 2011-03-09 | — | — | EP | disclosed |
| US-7429618-B2 | Potassium channel modulators | NEUROSEARCH A/S (DK) | 2008-09-30 | — | — | US | disclosed |
| US-7429618-B2 | Potassium channel modulators | NEUROSEARCH A/S (DK) | 2008-09-30 | — | — | US | disclosed |
| US-7429618-B2 | Potassium channel modulators | NEUROSEARCH A/S (DK) | 2008-09-30 | — | — | US | disclosed |
| EP-1911740-A1 | POTASSIUM CHANNEL MODULATORS | NeuroSearch A/S (DK) | 2008-04-16 | — | — | EP | disclosed |
| EP-1911740-A1 | POTASSIUM CHANNEL MODULATORS | NeuroSearch A/S (DK) | 2008-04-16 | — | — | EP | disclosed |
| US-20070161607-A1 | Potassium channel modulators | SANIONA A/S (DK) | 2007-07-12 | — | — | US | disclosed |
| US-20070161607-A1 | Potassium channel modulators | SANIONA A/S (DK) | 2007-07-12 | — | — | US | disclosed |
| US-7208527-B2 | Potassium channel modulators | POSEIDON PHARMACEUTICALS A/S (DK) | 2007-04-24 | — | — | US | disclosed |
| US-7208527-B2 | Potassium channel modulators | POSEIDON PHARMACEUTICALS A/S (DK) | 2007-04-24 | — | — | US | disclosed |
| US-7208527-B2 | Potassium channel modulators | POSEIDON PHARMACEUTICALS A/S (DK) | 2007-04-24 | — | — | US | disclosed |
| US-20050009816-A1 | Potassium channel modulators | SANIONA A/S (DK) | 2005-01-13 | — | — | US | disclosed |
| EP-1465863-A1 | POTASSIUM CHANNEL MODULATORS | Poseidon Pharmaceuticals A/S (DK) | 2004-10-13 | — | — | EP | disclosed |
| WO-2003059873-A1 | POTASSIUM CHANNEL MODULATORS | POSEIDON PHARMACEUTICALS A/S (DK) | 2003-07-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050009816-A1 | Potassium channel modulators | KCNC1, KCNQ1, KCNA1 | NR3C1 4520/4885GAA 3998/4885HTT 1226/4885 |
| US-20070161607-A1 | Potassium channel modulators | KCNC1, KCNQ1, KCNA1 | NR3C1 4520/4885GAA 3998/4885HTT 1226/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.